Abstract
Dacarbazine is widely used in the treatment of melanoma. Transient abnormalities of liver function tests are well-recognised side effects of the drug, but acute liver failure due to vascular occlusion in patients receiving single-agent chemotherapy with dacarbazine has been noted only rarely. Two cases are reported in which hepatic vascular lesions developed during treatment with dacarbazine and were confirmed at necropsy. Hepatic vascular occlusion due to treatment with dacarbazine may be less rare than was previously thought. Greater caution may be needed when dacarbazine is prescribed, particularly as an adjuvant agent in stage I and II disease.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Asbury R. F., Rosenthal S. N., Descalzi M. E., Ratcliffe R. L., Arseneau J. C. Hepatic veno-occlusive disease due to DTIC. Cancer. 1980 May 15;45(10):2670–2674. doi: 10.1002/1097-0142(19800515)45:10<2670::aid-cncr2820451031>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
- Houghton A. N., Shafi N., Rickles F. R. Acute hepatic vein thrombosis occurring during therapy for Hodgkin's disease: a case report. Cancer. 1979 Dec;44(6):2324–2329. doi: 10.1002/1097-0142(197912)44:6<2324::aid-cncr2820440648>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
- Johnson R. O., Metter G., Wilson W., Hill G., Krementz E. Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group. Cancer Treat Rep. 1976 Feb;60(2):183–187. [PubMed] [Google Scholar]
- Lehrner L. M., Enck R. E. Hepatic-vein thrombosis after chemotherapy for histiocytoma. Ann Intern Med. 1978 Apr;88(4):575–576. doi: 10.7326/0003-4819-88-4-575_2. [DOI] [PubMed] [Google Scholar]